Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma

Cancer Investigation

Volumn 21, Issue 5, 2003, Pages 682-689

  Le, Duc Thanh ^a   Deavers, Michael ^a   Hunt, Kelly ^a   Malpica, Anais ^a   Verschraegen, Claire F ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Intraperitoneal therapy; Mesothelioma; Topoisomerase inhibitors

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; CA 125 ANTIGEN; CISPLATIN; DIPHENHYDRAMINE; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GRANULOCYTOPENIA; HEARING LOSS; HUMAN; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RECTUM HEMORRHAGE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0242413753     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120023766     Document Type: Article

References (32)

1. Markman, M.; Kelsen, D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J. Cancer Res. Clin. Oncol. 1992, 118 (7), 547-550.
2. Verschraegen, C.; Mansfield, P.; Feig, B.; Steger, M.; Wu, Q.; MacLean, D.; Siddik, Z.; Perez-Soler, R.; Hu, W.; Kudelka, A.; Kavanagh, J.; Khokhar, A. Phase I study of an intraperitoneal liposomal cisplatin analog 1-nddp for treatment of peritoneal carcinomatosis. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999, 18, A1405.
3. Mintzer, D.M.; Kelsen, D.; Frimmer, D.; Heelan, R.; Gralla, R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 1985, 69 (6), 711-712.
4. Noda, W.; Nishiwaki, Y.; Kawahara, M.; Negoro, S.; Sugiura, T.; Yokoyama, A.; Fukuoka, M.; Mori, K.; Watanabe, K.; Tamura, T.; Yamamoto, S.; Saijo, N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl. J. Med. 2002, 346 (2), 85-91.
5. Adachi, S.; Ogasawara, T.; Yamasaki, N.; Shibahara, H.; Kanazawa, R.; Tsuji, Y.; Takemura, T.; Koyama, K. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn. J. Clin. Oncol. 1999, 29 (9), 434-437.
6. Boku, N.; Ohtsu, A.; Shimada, Y.; Shirao, K.; Seki, S.; Saito, H.; Sakata, Y.; Hyodo, I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 1999, 17 (1), 319-323.
7. Ilson, D.H.; Saltz, L.; Enzinger, P.; Huang, Y.; Kornblith, A.; Gollub, M.; O'Reilly, E.; Schwartz, G.; DeGroff, J.; Gonzalez, G.; Kelsen, D.P. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 1999, 17 (10), 3270-3275.
8. Sugiyama, T.; Yakushiji, M.; Noda, K.; Ikeda, M.; Kudoh, R.; Yajima, A.; Tomoda, Y.; Terashima, Y.; Takeuchi, S.; Hiura, M.; Saji, F.; Takahashi, T.; Umesaki, N.; Sato, S.; Hatae, M.; Ohashi, Y. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000, 58 (1), 31-37.
9. Nakano, T.; Chahinian, A.P.; Shinjo, M.; Togawa, N.; Tonomura, A.; Miyake, M.; Ninomiya, K.; Yamamoto, T.; Higashino, K. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999, 85 (11), 2375-2384.
10. Lederman, G.S.; Recht, A.; Herman, T.; Osteen, R.; Corson, J.; Antman, K.H. Combined modality treatment of peritoneal mesotheliomas. NCI Monogr. 1988, 6, 321-322.
11. Ma, G.Y.; Bartlett, D.L.; Reed, E.; Figg, W.D.; Lush, R.M.; Lee, K.B.; Libutti, S.K.; Alexander, H.R. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J. Sci. Am. 1997, 3 (3), 174-179.
12. Sebbag, G.; Yan, H.; Shmookler, B.M.; Chang, D.; Sugarbaker, P.H. Results of treatment of 33 patients with peritoneal mesothelioma. Br. J. Surg. 2000, 87 (11), 1587-1593.
13. Ball, D.; Cruickshank, D. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am. J. Clin. Oncol. 1990, 13, 4-9.
14. Gordon, W.; Antman, K.; Greenberger, J.; Weichselbaum, R.; Chaffey, J. Radiation therapy in the management of patients with mesothelioma. Int. J. Rad. Oncol. Biol. Phys. 1982, 8, 19-25.
15. Taub, R.N.; Antman, K.H. Chemotherapy for malignant mesothelioma. Semin. Thor. Cardiovasc. Surg. 1997, 9 (4), 361-366.
16. Kindler, H.L.; Millard, F.; Herndon, J.E., II. Vogelzang, N.J.; Suzuki, Y.; Green, M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31 (2-3), 311-317.
17. Taub, R.; Keohan, M.L.; Vogelzang, N.J.; Costanzi, J.; Chun, H.; Mittelman, A.; Panella, T.; McCachren, S.; Puccio, C.; Shogen, K.; Fine, R.; Mikulski, S.M. Phase II trial of onconase (onc) in patients (pts) with advanced malignant mesothelioma (mm): analysis of survival. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999, 18, A2021.
18. Le Chevallier, T. Multi-targeted antifolate therapy for non-small cell lung cancer and mesothelioma. Anti Cancer Drugs 2001, 12 (3), 21-25.
19. Tsunoda, T.; Tanimura, H.; Hotta, T.; Tani, M.; Iwahashi, M.; Ishimoto, K.; Tanaka, H.; Matsuda, K.; Yamaue, H. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. J. Surg. Oncol. 2000, 73 (1), 6-11.
20. Kanzawa, F.; Nishio, K.; Fukuoka, K.; Fukuda, M.; Kunimoto, T.; Saijo, N. Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Int. J. Cancer 1997, 71 (3), 311-319.
21. Goldwasser, F.; Valenti, M.; Torres, R.; Kohn, K.W.; Pommier, Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res. 1996, 2 (4), 687-693.
22. Albain, K.S.; Swinnen, L.J.; Erickson, L.C.; Stiff, P.J.; Fisher, S.G.; Fisher, R.I. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. Sem. Oncol, 1992, 19 (3 Suppl 9), 102-109.
23. Shin, D.; Fossella, F.; Umawasdi, T. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant peritoneal mesothelioma. Cancer 1995, 76, 2230-2236.
24. Markman, M. Intraperitoneal chemotherapy: a rational approach to overcome drug resistance. In Clinical Management of the Drug resistant Cancer Patient: New Options in Clinical Oncology; Nagoumey, R.A., Sheikh, K.M., Eds.; Memorial Medical Center Foundation: Long Beach, CA, 1991; 85-105.
25. Alberts, D.S.; Liu, P.Y.; Hannigan, E.V.; O'Toole, R.; Williams, S.D.; Young, J.A.; Franklin, E.W.; Clarke-Pearson, D.L.; Malviya, V.K.; DuBeshter, B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Eng. J. Med. 1996, 335 (26), 1950-1955.
26. Takiyama, I.; Terashima, M.; Ikeda, K.; Kawamura, H.; Sasaki, N.; Hayakawa, Y.; Ishida, K.; Saito, K. Remarkable synergistic interaction between camptothecin analogs and cisplatin against human esophageal cancer cell lines. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1997, 38, A101.
27. Verschraegen, C.; Le, D.; Kudelka, A.; Kavanagh, J.; Hunt, K.J. Cisplatin and irinotecan for peritoneal mesothelioma. Proc. Am. Soc. Clin. Oncol. 2001, 20, A2110.
28. Azevedo, P.; Verschraegen, C.F.; Kavanagh, J.J.; Kudelka, A.P.; Freedman, R.S.; Lu, K.; Deavers, M.T. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. Eur. J. Gynaecol. Oncol. 2001, 22 (5), 319-321.
29. Verschraegen, C.F.; Levy, T.; Kudelka, A.P.; Llerena, E.; Ende, K.; Freedman, R.S.; Edwards, C.L.; Hord, M.; Steger, M.; Kaplan, A.L.; Kieback, D.; Fishman, A.; Kavanagh, J.J. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 1997, 15 (2), 625-631.
30. Balat, O.; Verschraegen, C. Topoisomerase I inhibitors in gynecologic cancers. Expert Opin. Investig. Drugs 1995, 4, 1217-1230.
31. Vlasveld, L.T.; Gallee, M.P.; Rodenhuis, S.; Taal, B.G. Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur. J. Cancer 1991, 27 (6), 732-734.
32. Langer, C.J.; Rosenblum, N.; Hogan, M.; Nash, S.; Bagchi, P.; LaCreta, F.P.; Catalano, R.; Comis, R.L.; O'Dwyer, P.J. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother. Pharmacol. 1993, 32 (3), 204-208.